Latest MS news
Introducing Octopus
We’re pleased to introduce Octopus - our revolutionary, multi-arm, multi-stage trial that will transform the way we test treatments for progressive MS.
With recruitment starting later this year, Octopus will provide a smarter way of testing potential MS drugs. This could deliver life-changing new treatments up to three times faster.
NICE approve ofatumumab (Kesimpta) for active relapsing MS
The National Institute for Health and Care Excellence (NICE) has approved ofatumumab as a new treatment option for relapsing MS in adults with active disease.
Ofatumumab is the first self-administered B-cell targeting therapy to be licensed in the UK.
Our Medical Advisers consensus statement on MS treatments and COVID-19 vaccines
Could a COVID-19 vaccine cause a relapse? Will the vaccine work even though I’m on a DMT?
We asked our medical advisors to answer your questions about what the new coronavirus vaccine means if you're on an MS treatment.
Together we can stop MS
We’ve never been closer to stopping MS than we are today.
Coronavirus has slowed down our progress, but stopping MS is still within our grasp. We won’t give up until we find treatments for everyone.
Our new membership offer
At last year's AGM our members voted to change our membership model. Membership is now free.
These changes will help us support more people and build a stronger community, so we can keep delivering vital support services and world-leading research.
The next research breakthrough is in reach
Your donation will help stop MS.
One-off donation
Monthly donation
Find support near you
We can't meet face-to-face right now. But there's still lots of ways to connect with people near you who understand what life's like with MS. From coffee mornings to online yoga classes. Put in your postcode to find out what's near you.
Together we can stop MS
Today MS affects thousands of lives across the UK.
But we've got a plan to change that. Will you help?
You can hear an audio described version of this video on our YouTube channel.